Jefferies initiates coverage on Cirsa Enterprises stock with Buy rating

Jefferies initiated coverage on Cirsa Enterprises SA with a Buy rating and a EUR20.00 price target, citing the company's "unique, diverse, 100% regulated gaming platform" and an "enviable track record" of 67 consecutive quarters of EBITDA growth (ex-COVID), achieving a 13% CAGR from FY2005-2024. The firm projects 8% EBITDA growth for FY2025-2027, further supported by Cirsa's experienced management team and potential for accelerated M&A spend, signaling a strong investment thesis for the gaming company.

Analysis

Jefferies has initiated coverage on Cirsa Enterprises SA with a 'Buy' rating and a EUR20.00 price target, signaling a strongly positive outlook. The investment thesis is built on Cirsa's unique position as a fully regulated and diversified gaming platform, which has demonstrated significant historical resilience and growth. The firm highlights an exceptional track record of 67 consecutive quarters of EBITDA growth, excluding the COVID-19 impact, which translates to a 13% compound annual growth rate (CAGR) for its EBITDA from fiscal year 2005 to 2024. Looking forward, Jefferies projects a continuation of this momentum, albeit at a more moderate pace, targeting 8% EBITDA growth for the fiscal years 2025-2027. Confidence in this forecast is further supported by Cirsa's long-tenured management team, noted for its successful M&A execution, and the potential for accelerated growth driven by increased M&A spending.

Key Decisions for Investors

• Investors should evaluate the bullish thesis presented by Jefferies, which is underpinned by a strong historical EBITDA growth track record of 13% CAGR and a positive forward-looking projection of 8% growth.
• Closely monitor the company's M&A activity, as Jefferies identifies accelerated deal-making as a key potential catalyst for upside beyond the baseline growth forecasts.
• Consider the EUR20.00 price target as a key valuation benchmark, assessing potential entry points relative to this analyst-projected upside while also monitoring for corroborating research to validate the single-source initiation.